for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials

PARIS (Reuters) - France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.

Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.

Reporting by Laurence Frost; Editing by Mark Potter

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up